CVS Caremark replaces Zepbound with Wegovy on its preferred medication list, requiring patients to change.
CVS Caremark Drops Zepbound, Shifts to Wegovy for Weight Loss Many patients using GLP-1 medications for weight loss are navigating a frustrating shift due to changes in insurance coverage. With CVS Caremark, one of the major pharmacy benefit managers in the U.S., announcing it will discontinue coverage for Zepbound (Tirzepatide) as of July 1, this […]
Wegovy producer Novo Nordisk lowers profit expectations as US prescriptions decline.
Novo Nordisk in Denmark has cut its annual revenue and profit projections due to a slowdown in Wegovy sales, a weight loss medication, as prescriptions in the US have declined. The success of Wegovy, along with booming sales of diabetes drugs, elevated these companies to the status of Europe’s most valuable publicly traded firms, reaching […]
Ozempic and Wegovy may be able to reverse serious liver disease, research indicates
Recent research indicates that medications designed for diabetes and weight management may halt or even reverse serious liver conditions. A study led by Virginia Commonwealth University has highlighted that semaglutide, often marketed as Ozempic or Wegovy, can be effective against metabolic dysfunction-associated steatohepatitis (MASH) and its related risk factors. MASH is characterized by inflammation and […]
Hims & Hers to offer Wegovy thanks to new partnership with Novo Nordisk
Please see what you are clicking on foxbusiness.com. Hims & Hers Health announced on Tuesday that it will bundle Telehealth Platform membership and Wegovy through a new collaboration with drug maker Novo Nordisk. The bundle offers all doses combined with Novo Nordisk's popular weight loss medication with HIMS & HERS membership, providing “24/7 care, ongoing […]
Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers
Novo Nordisk said Wednesday it will begin selling its weight loss drug Wegovy at a discounted $499 per month to cash-paying patients as it is working towards a transition to competitive dynamics in the US obesity drug market. The move comes more than a week after rival Eli Lily cuts the price of weight loss […]
Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy
Drug manufacturer Novo Nordisk announced Wednesday that it will offer a program directly from patients so that uninsured and uninsured individuals can pay cash at significantly reduced costs for weight-reduced products. The drugmaker has appointed a new program, Novocare® Pharmacy. It sells all dose strengths from Wegovy for $499 per month. Most patients pay a […]
Novo Nordisk shares plummet after successor to Wegovy disappoints in study
Novo Nordisk announced on Friday disappointing results from a late-stage trial of its experimental next-generation obesity drug Kaglisema, wiping its market value by $125 billion. The drug candidate's lower-than-expected weight loss is a blow to the Danish company's ambitions to replace its weight-loss drug Wegoby, which is more powerful than Eli Lilly's rival Zepbound (also […]
Biden proposes weight-loss drugs Ozempic, Wegovy be covered by Medicare and Medicaid
Millions of obese Americans would be eligible to receive popular weight-loss drugs like Wigoby and Ozempic covered by Medicare or Medicaid under new rules proposed by the Biden administration Tuesday morning. A costly proposal from the U.S. Department of Health and Human Services is the latest in a potential showdown between the powerful pharmaceutical industry […]
Ozempic, Wegovy and other GLP-1s shown to reduce alcohol-related hospitalizations
Ozempic, Wigovy and other GLP-1 drugs have been shown to counteract the effects of alcohol, a new study suggests. Glucagon-like peptide-1 receptor (GLP-1) agonists (including either semaglutide or liraglutide), which are prescribed to treat type 2 diabetes and obesity, have been reported to reduce alcohol intake when taken. Previous research has shown that. A new […]
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy
Weight Watchers CEO Sima Sistani abruptly resigned on Friday after a two-year tenure that included controversial adoption of weight-loss drugs such as Ozempic and Wigovy. Sistani pushed the 61-year-old company, known for its in-person meetings and portion control, to buy a telemedicine platform that connects patients with doctors who can prescribe popular obesity drugs. But […]